Close Menu

NEW YORK (GenomeWeb) – Molecular diagnostics firm Bioarray Genetics on Thursday said that it has received $4 million in Series B equity financing.

The funding came from Quark Venture and GF Securities through their Global Health Science Fund and Connecticut Innovations, and will be used to move Bioarray Genetics' first product, BA100, a breast cancer diagnostic, to clinicians. The financing will also be used for R&D for other tests, including those targeting treatments for metastatic breast and colon cancers, the firm said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Hill reports President Donald Trump issued an executive directing federal agencies to cut the number of board and advisory committees they have.

The New York Times reports that researchers are combining tools to more quickly develop crops to feed a growing population and cope with shifting climates.

Scientists in Canada are looking to the UK's plan to sequence children with rare conditions for inspiration, the National Post reports.

In PNAS this week: copy number changes arose during polar bear evolution, genomic and transcriptomic analysis of the Siberian hamster, and more.